Skip to main content

Osteoarthritis Hand

4
Pipeline Programs
2
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Chong Kun Dang Pharmaceutical
1 program
1
Celecoxib 100 MGPhase 41 trial
Active Trials
NCT03067194Completed117Est. Nov 2018
TBF Genie Tissulaire
TBF Genie TissulaireFrance - Mions
3 programs
3
MENISC-TPhase 21 trial
SclerFIX-IPPhase 21 trial
SclerFIX-IPPhase 21 trial
Active Trials
NCT05250726Completed14Est. Feb 2024
NCT06034262Terminated1Est. Oct 2025
NCT06038331Active Not Recruiting14Est. Nov 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Chong Kun Dang PharmaceuticalCelecoxib 100 MG
TBF Genie TissulaireSclerFIX-IP
TBF Genie TissulaireSclerFIX-IP
TBF Genie TissulaireMENISC-T

Clinical Trials (4)

Total enrollment: 146 patients across 4 trials

The Study to Evaluate Efficacy and Safety of Celecoxib Capsule in Hand Osteoarthritis Patients

Start: Dec 2016Est. completion: Nov 2018117 patients
Phase 4Completed

Use of a Treated, Devitalized and Sterile Umbilical Cord Amniotic Membrane in the Treatment of PIP Joint Osteoarthritis

Start: Oct 2024Est. completion: Oct 20251 patients
Phase 2Terminated

Use of a Treated, Devitalized and Sterile Umbilical Cord Amniotic Membrane in the Treatment of STT Osteoarthritis

Start: May 2024Est. completion: Nov 202614 patients
Phase 2Active Not Recruiting

Use of a Treated, Devitalized and Sterile Meniscus Segment (MENISC-T) in the Treatment of Scaphotrapeziotrapezoid Osteoarthritis

Start: Jan 2021Est. completion: Feb 202414 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.